Product Description
Synapsinae is a potent Glycine Transporter 1 (GlyT-1) inhibitor. Inhibition of GlyT-1 can block glycine uptake and enhance the function of NMDA receptor. (Sourced from: https://www.syneurx.com/research/#pipeline)
Mechanisms of Action: GlyT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SyneuRx
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Dementia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|